



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE
DELLA RICERCA

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Gaimari A., Fusaroli M., Raschi E., Baldin E., Vignatelli L., Nonino F., et al. (2022). Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. *DRUG SAFETY*, 45(6), 663-673 [10.1007/s40264-022-01184-1].

Availability:

This version is available at: <https://hdl.handle.net/11585/899160> since: 2022-11-03

Published:

DOI: <http://doi.org/10.1007/s40264-022-01184-1>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

TITLE PAGE**Title:**

Amyotrophic lateral sclerosis as an adverse drug reaction: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System

Authors:

Anna Gaimari^{*}, Michele Fusaroli^{*}, Emanuel Raschi^{*}, Elisa Baldin[†], Luca Vignatelli[†],
Francesco Nonino[†], Fabrizio De Ponti^{*}, Jessica Mandrioli^{‡, §}, Elisabetta Poluzzi^{*}

^{*}Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

[†]IRCCS Istituto delle Scienze Neurologiche di Bologna, Epidemiology and Statistics Unit, Bologna, Italy.

[‡]Neurology Unit, Azienda Ospedaliero-Universitaria di Modena Ospedale Civile di Baggiovara, Modena, Italy.

[§]Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Article type: original article

Running title: Amyotrophic lateral sclerosis as an adverse drug reaction

Corresponding Author:

Jessica Mandrioli

1 Department of Biomedical, Metabolic and Neural Sciences, University of Modena and
2 Reggio Emilia, Modena, Italy Neurology Unit, Azienda Ospedaliero-Universitaria di

3
4
5 Modena, Ospedale Civile di Baggiovara, Modena, Italy

6
7 Via Pietro Giardini 1355 IT-41126 Modena (Italy).

8
9
10 Tel. 00390593961640

11
12 Fax 00390593963375

13
14 E-Mail: jessica.mandrioli@unimore.it; madrioli.jessica@aou.mo.it
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a fatal progressive disease with a still unclear multifactorial etiology. This study focused on the potential relationship between drug exposure and the development of ALS by performing a detailed analysis of events reported in the FDA Adverse Event Reporting System (FAERS) database.

METHODS

The FAERS quarterly data (January 2004-June 2020) were downloaded and deduplicated. The reporting odds ratios (RORs) and their 95% confidence intervals (95% CIs) were calculated as a disproportionality measure. The robustness of the disproportion was assessed accounting for major confounders (i.e., using a broader query, restricting to suspect drugs, and excluding reports with ALS as an indication). Disproportionality signals were prioritized based on their consistency across analyses (ROR stability).

RESULTS

1188 ALS cases were retained. Sixty-two drugs showed significant disproportionality for ALS onset in at least one analysis, and 31 had consistent ROR stability, including TNF- α inhibitors and statins. Disproportionality signals from ustekinumab, an immunomodulator against interleukins 12-23 used in autoimmune diseases, and the anti-IgE omalizumab were consistent among analyses and unexpected.

CONCLUSIONS

For each drug emerging as possibly associated with ALS onset, biological plausibility, underlying disease and reverse causality could be argued. Our findings strengthened the plausibility of a precipitating role of drugs primarily through immunomodulation (e.g., TNF- α , ustekinumab, omalizumab), but also by impacting metabolism and the musculoskeletal integrity (e.g., statins and bisphosphonates). Complement and NF- κ B dysregulation could

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

represent interesting topics for planning translational mechanistic studies on ALS as an adverse drug effect.

KEY POINTS

- Amyotrophic lateral sclerosis (ALS) has a complex, unclear etiology including genetic susceptibility and environmental factors.
- By analyzing reports from the FDA Adverse Event Reporting System, 31 drugs were found to be disproportionally reported with ALS, including drugs potentially implicated in ALS development (e.g., immunomodulators, statins).
- Future translational research should focus on the possible role of complement and NF- κ B dysregulation in ALS onset or worsening.

MAIN TEXT

1. INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a rare, subtle, and progressive disease beginning with focal weakness, then spreading to involve most muscles. Patients die due to respiratory paralysis when the diaphragm is involved, in 3 to 5 years from symptoms onset. Disease progression is highly variable among affected individuals, and clinical features encompass heterogeneous motor and nonmotor signs and symptoms [1]. Therefore, late diagnosis is common.

Medications to relieve symptoms are available, together with two specific agents, riluzole and edaravone, which demonstrated a survival benefit of months.

One of the reasons accounting for the failure of almost all previous attempts with clinical trials in ALS is the incomplete comprehension of the pathogenic processes that cause disease onset and progression. Although ALS is a clinically defined syndrome where upper and lower motor neurons degenerate, the pathogenesis is probably heterogeneous across individual cases. It has been suggested that multiple events need to befall, or multiple factors need to be present for the disease to manifest. Presumably, these would include genetic susceptibility and environmental factors. Nonetheless, no specific environmental factor has been proven to cause ALS, and there is a remarkable gap between the relative abundance of proposed genetic ALS determinants and the lack of findings on environmental risk. Of note, the two drugs used to prolong life in patients diagnosed with ALS are thought to act directly on the survival of the motor neurons: edaravone as a free radical scavenger that prevents oxidative stress damage [2], riluzole inhibiting the glutamatergic excitotoxicity that results in high levels of intracellular calcium and free radicals generation [3].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Drugs exposure has been investigated as a potential risk/precipitating factor in the occurrence of ALS. Population-based observational studies (case-control design) found no association with proton pump inhibitors, an association with antibiotics, contradictory results for statins and tumor necrosis factor-alpha (TNF- α) inhibitors, and a potential inverse association with antidiabetics [4-7]. Of note, gut microbiota, altered by several of these drugs, was proposed as a working hypothesis [8].

Large-scale post-marketing databases are suitable sources to suggest potential associations between specific drug exposures and rare events, such as ALS, which may escape detection and/or reporting from randomized controlled trials and population-based studies [9]. Of note, real-world pharmacovigilance databases have been used to investigate the role of drugs in modulating complex and multifactorial neuropsychiatric diseases such as multiple sclerosis, thus supporting clinicians in real-life risk-benefit evaluation [10].

The aim of this study is to characterize spontaneous reports of ALS using one of the largest publicly available repositories of adverse events, namely the FDA Adverse Event Reporting System (FAERS), in order to assess whether specific drug exposures could represent a potential risk or precipitating factor in ALS development.

2. METHODS

2.1 Study design and Data source

The study was conceived as a case/non-case analysis using the FAERS, a surveillance system collecting reports submitted on a voluntary basis by healthcare professionals and consumers. Reports may be submitted directly to the FDA using MedWatch forms but are usually submitted first to the Marketing Authorization Holders, for which forwarding to the FDA is mandatory. It currently collects more than 20 million reports worldwide (including European reports potentially related to serious events and other non-US non-European data), with public

1 data availability since 2004, thus offering an emerging opportunity for signal detection and
2 characterization [9]. Adverse events and indications are coded using the Medical Dictionary
3 for Regulatory Activities (MedDRA®) preferred terms (PTs). Drug names, instead, are
4 recorded as a free text and are, therefore, extremely heterogenous (e.g., referring to the brand
5 or the active ingredient, not uncommonly with misspellings).
6
7
8
9

10 We downloaded the FAERS quarterly data (January 2004-June 2020) and pre-processed them
11 for drug name standardization. We used the WHOdrug dictionary (accessed in March 2020)
12 and manual integration to reach a coverage of more than 97% of the recorded drugs, which
13 were translated into their active ingredients and referred to their class in the Anatomic
14 Therapeutic Chemical (ATC) classification. Further, a semiautomatic algorithm was used to
15 keep only the last update of each report and to remove duplicates (i.e., reports with the same
16 sex, age, weight, country, event date, list of drugs, and list of events) [11].
17
18
19

20 No ethics board was needed since this was a pharmacovigilance analysis using an existing
21 database with anonymous public data availability.
22
23
24
25
26
27

28 2.2 Disproportionality analyses

29 A pre-specified multi-step strategy was applied to assess the consistency of findings and
30 minimize bias.
31
32
33
34
35
36

37 To evaluate if, and to what extent, ALS was reported as a potential adverse drug reaction, we
38 performed a disproportionality analysis, a consolidated approach in pharmacovigilance.
39 Through the so-called case/non-case approach, the reporting odds ratio (ROR) was calculated
40 and deemed statistically significant when the lower limit of its 95% confidence interval
41 (95%CI) exceeded 1 [11]. If the proportion of ALS reports was greater among patients exposed
42 to a specific drug (cases) than among patients not exposed to it (non-cases), an association was
43 hypothesized (disproportionality signal).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Notably, the performance of the ROR (i.e., the capacity to discriminate true from false positive
2 drug–event associations) is striking especially for adverse events with low/rare background
3 incidence such as ALS [12].
4

5
6 As the main analysis, we calculated the ROR between the PT “amyotrophic lateral sclerosis”
7 and individual active ingredients. In this analysis, we recognized a report as a case both whether
8 the drug was recorded as the suspect therapy or whether it was recorded as concomitant
9 therapy. This choice was made because it may be difficult to identify the culprit for the
10 development of a plausibly delayed onset reaction as ALS, and because, if we are considering
11 concomitant therapy as non-case, then the same drug would appear both at the numerator and
12 the denominator of the ROR formula.
13
14

15 To assess the robustness of the disproportionality signal, we performed three other
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

To increase the sensitivity of our study we considered 1) a broader ALS definition for case retrieval, including also “familial ALS”, “hereditary ALS”, “motor neuron disease”, “progressive bulbar palsy”, and “progressive muscular atrophy”. This way we could account for the redundancy in MedDRA terms, for which ALS may be recorded using different terms depending on the reporter. To increase the specificity of the study we restricted the disproportionality analysis to 2) drugs recorded as primary or secondary suspects, and 3) reports without ALS among the specified indications. This way we could account for the judgment of the reporter on the drug role, and for the expected association between ALS and drugs used in its management. In particular, we decided to exclude drugs used to treat ALS only in a specific analysis because the reverse causality bias (i.e., the fact that a disproportion may be the result of drugs being taken to treat ALS or its symptoms) cannot be completely foreseen. This is true, in particular, for drugs used to treat ALS prodromes, which are less specific and develop before the diagnosis.

1
2 To further reduce the likelihood of false positives, the ROR was calculated only for drugs with
3 at least 5 cases.

4
5 Disproportionality signals were prioritized based on their consistency across the different
6 analyses (ROR stability). Finally, aiming for maximum specificity, we focused on the drugs
7 with the top ROR stability: all the analyses detected a significant ROR.
8
9

10 11 12 13 14 **3. RESULTS**

15
16 Overall, 14,526,399 reports were downloaded from the FAERS quarterly data and reduced to
17 10,760,574 with the de-duplication process. Among these, 1,181 reports specified ALS as a
18 reaction (1,464 using the broader definition), 543 (44%) recording ALS as the only adverse
19 event. The geographical areas contributing with more reports were North America (405,
20 34.1%), Europe (181, 15.2%), Asia (60, 5.1%), and South America (23, 1.9%).
21
22

23
24 ALS reports occurred more commonly in males, peaked between 50 and 74 years old, and were
25 submitted after 2012.
26
27

28
29 Sixty-two drugs were disproportionally reported with ALS using the broad definition. Of these,
30 31 drugs kept the signal in all more specific analyses, 5 drugs in 3 and 17 drugs in 2 (see Table
31
32
33
34
35
36
37
38
39 1). For further information about case numbers and RORs calculated in the analyses, see the
40 supplementary table in the Online Resource.
41

42
43 Some pharmacological classes included more drugs disproportionally reported with ALS.
44 Concerning cardiovascular/metabolic drugs, all marketed statins showed a “top” ROR stability
45 (4 out of 4 analyses) and a high number of cases (atorvastatin, 154 –main ROR = 4.97, 95%CI
46 = 4.19-5.88 –; simvastatin, 95 – 4.01, 3.25-4.94 –; rosuvastatin, 58 – 4.34, 3.33-5.65–). Only a
47 small decrease in cases was observed in the more specific analyses. As for other drugs in the
48 cardiovascular area, atenolol, enalapril, and candesartan were recorded in a non-negligible
49 number of cases (respectively, 27, 15, 19), but with a lower ROR stability.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Concerning immunomodulating agents, TNF- α inhibitors showed the highest number of cases (adalimumab, 99 -2.03, 1.65-2.49-; etanercept, 89 -1.76, 1.42-2.19-; infliximab, 78 -5.46, 4.34-6.87-). Notable findings were also obtained for ustekinumab (top ROR stability, with 10 cases -2.04, 1.10, 3.81-) and omalizumab (top ROR stability with 8 cases -2.06, 1.03-4.12-). Among antineoplastic agents, methotrexate (2.46, 1.97-3.09) and rituximab (3.3, 2.37-4.59) had the top ROR stability and the highest number of cases. However, the 99 broad cases of methotrexate decrease to 41 when restricting to suspect drugs and cases without ALS in the indications.

Regarding musculoskeletal system drugs, we observed top ROR stability for risedronic acid (7 -2.57, 1.22-5.41-), baclofen (28 -3.61, 2.48-5.26-), and celecoxib (19 -1.91, 1.21-3-). Among nervous system drugs, only duloxetine showed a top ROR stability.

Edaravone and riluzole, the only two drugs labeled for ALS treatment, showed a disproportionality signal only in the first three case definitions, losing it in the correction for the reverse causality bias.

We also observed top ROR stability for dextromethorphan (17 -7.51, 4.65-12.12-).

Three agents belonging to different therapeutic classes, but with a common quinolinic chemical structure and antinicotinic activity, emerged with not negligible cases and disproportionality signal: quinidine (16 -40.18, 24.51-65.88-, top ROR stability), hydroxychloroquine (19 -2.11, 1.34-3.32-, top ROR stability) and quinine (3 -3.21, 1.03-9.97-, Intermediate ROR stability).

4. DISCUSSION

1 We investigated ALS from a pharmacovigilance perspective and found a higher-than-expected
2 reporting (disproportionality signal) for 62 different drugs, especially TNF- α inhibitors and
3
4 statins, thus supporting the hypothesis that drug exposure can have a role in ALS onset. For
5
6 every single drug or drug class, the biological plausibility of the adverse drug effect was
7
8 discussed, accounting for a potential reverse causality bias between indication for use and ALS.
9
10

11 ***Role of immunomodulators***

12
13 Immunomodulator agents had the highest number of signals, especially TNF- α inhibitors
14
15 (adalimumab, infliximab, etanercept, abatacept). They are usually prescribed to treat chronic
16
17 inflammatory/autoimmune diseases (e.g., rheumatoid arthritis and psoriasis), although some
18
19 preliminary studies proposed them even as a potential treatment for ALS, due to their ability
20
21 in reducing microglial inflammation [13].
22
23
24

25
26 As a matter of fact, specific autoimmune mechanisms responsible for the loss of motoneurons
27
28 have been advocated as factors promoting ALS. In particular, complement dysregulation and
29
30 deposition have been identified at the neuromuscular junction prior to nerve cell death in ALS
31
32 patients [14]. The role of complement in ALS was confirmed in animal models [15,16] and
33
34 indeed two randomized clinical trials on complement inhibitors (ravulizumab and
35
36 pegcetacoplan) in ALS patients are currently ongoing [17,18]. Since upregulation of TNF- α
37
38 causes complement induction, TNF- α inhibitors could hamper ALS progression.
39
40
41

42
43 On the other hand, TNF- α inhibitors may also represent a risk factor for ALS onset and
44
45 progression [13]. This “Janus effect” results from their ability to both activate the PI3K/Akt
46
47 pathway and inhibit the NF- κ B-dependent pathways, which are the major survival pathways in
48
49 motor neurons [19]. Clinical evidence is also conflicting: some reports, indeed, describe ALS
50
51 onset in patients with autoimmune diseases treated with TNF- α inhibitors (adalimumab) [20],
52
53
54 but a population-based cohort study did not find an increased incidence of ALS in patients with
55
56 rheumatoid arthritis, regardless of treatment with TNF- α inhibitors [7].
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Other immunosuppressants also emerged. The signal of ustekinumab, a fully-humanized monoclonal antibody that binds the p40 subunit of unbound Interleukin (IL) 12 and 23, used in inflammatory bowel diseases and psoriasis, found support in a case report where its use anticipated ALS onset [21]. The signal of omalizumab, an IgE antagonist monoclonal antibody mainly used in severe asthma and allergic respiratory diseases, seems completely unexpected. The signal of hydroxychloroquine, frequently used for its immunosuppressive properties (e.g., in rheumatoid arthritis), is partly supported by evidence on other hydroxychloroquine-induced neuromuscular disorders (i.e., myasthenia gravis) [22].

Our findings from the FAERS suggest that a patient who starts receiving immunomodulating drugs to treat autoimmune diseases may have a greater susceptibility to ALS either for the drug or for the underlying autoimmunity. Going forward, translational medicine studies and larger cohort studies should be carried on, in order to further investigate this relationship between each specific agent (or the whole pharmacological class) and ALS development.

Role of antineoplastic agents

Concerning antineoplastic drugs, we observed statistically significant data for imatinib, rituximab, and methotrexate, the most commonly prescribed drugs of their respective class.

Other agents with the same mechanisms could share this effect, but their less common use probably limited the number of reports and hampered the achievement of significant disproportionality.

Rituximab's mechanism of action includes direct effects with complement-mediated cytotoxicity together with antibody-dependent cell-mediated cytotoxicity [23]. Furthermore, treatment with methotrexate is associated with systemic complement activation [24]. The complex activities of these drugs leading to complement activation may be implicated in ALS pathogenesis.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Of interest, the case of imatinib, an oral tyrosine kinase inhibitor (TKI) targeting c-KIT, which also inhibits TNF- α production and could reduce the survival of astrocytes, similarly to other TNF- α inhibitors [25]. Masitinib, analog to imatinib with higher selectivity and potential better safety profile, was found to reduce neuroinflammation by targeting mast cells and neutrophils in pre-clinical models [26] and is now tested for ALS treatment in a phase III multicenter international RCT after a promising phase II study [27].

Overall, these data suggest a possible role of the drugs, rather than of the underlying diseases, as risk factors for ALS, and their multifaceted mechanisms of action deserve to be better explored in relation to ALS with preclinical and clinical studies.

Role of agents for metabolic-cardiovascular disorders

Top ROR stability for all statins emerged from our analyses. Statins are widely prescribed drugs and are generally considered safe medications, except for rare side effects such as myositis. As a matter of fact, according to Golomb B. et al. [28], we found higher disproportionality for lipophilic statins, for which the incidence of rhabdomyolysis is 4 times higher than for monotherapy with pravastatin and fluvastatin [29]. It could be argued that rhabdomyolysis (as well as the rare peripheral neuropathy [30]), caused by lipophilic statins, may uncover the onset of ALS.

On the other hand, high plasma cholesterol levels have been suggested to be neuroprotective for ALS and to be associated with an increased survival time. Statins, by lowering cholesterol inhibiting HMG-CoA reductase, may accelerate functional decline or clinical onset in patients inclined to ALS. Patients on statin therapy also reported a significant increase in muscle cramp frequency and severity [31].

By considering all these aspects, we can argue that statins may unmask preexisting ALS or worsen the disease. Given the milder muscular effects of ezetimibe [32], our findings on this drug may be due to a previous or concomitant use of statins.

1 As for antihypertensives, we found disproportionality for only a few drugs, with a strong
2 decrease in cases in the more sensitive analyses. Published evidence on patients with ALS from
3 clinical registries provides controversial findings on the impact of cardiovascular disorders on
4 ALS course: Moglia C. et al. observed that arterial hypertension, type 2 diabetes, and
5 cardiovascular risk factors do not influence ALS phenotype and prognosis [33]; while
6 Mandrioli J. et al., by performing a multicentre, retrospective study including patients in 13
7 referral centers for ALS located in 10 Italian regions, showed that patients with ALS affected
8 by hypertension at diagnosis had a median survival of 37 months as opposed to 49 months for
9 those who were not affected, by concluding that hypertension and heart diseases, as well as
10 hematological diseases, are independently associated with shorter survival [34]. Evidence on
11 the possible impact of cardiovascular drugs on ALS is even more scarce. It is of interest that
12 the riluzole mechanism of action also encompasses sodium and calcium channels modulation;
13 some drugs (e.g., verapamil) identified in our analysis could act oppositely. Beta-blockers
14 could instead worsen respiratory symptoms, by acting as antagonists on bronchial beta-2
15 receptors.

36 ***Role of bisphosphonates***

37 Bisphosphonates are used to treat patients with osteoporosis, to prevent hip and vertebral
38 fractures, and among known side effects, paradoxical bone damage is included: osteonecrosis
39 of the jaw (ONJ) and atypical femoral fracture. Our findings on bisphosphonates as possible
40 risk factors for ALS onset may be due to different reasons. First, patients on bisphosphonates
41 to treat osteoporosis might already have non-diagnosed ALS. Consequently, reporters could
42 have inappropriately identified bisphosphonates as a suspected cause for ALS onset. Bone
43 mineral loss has been noted in ALS and aberrant calcium metabolism and vertebral anomalies
44 have been detected in some patients with ALS [35], and according to the study by Peters T.L.
45 et al poor bone health may be related to ALS [36]. There are in fact some common features

1
2 that may link ALS and osteoporosis, including the influence of several neurotoxic metals, such
3 as lead and the age at onset [37].

4
5 Again, ALS worsening might depend on paradoxical side effects of bisphosphonates on bone
6 growth, already affected in ALS. In fact, it is likely that skeletal muscle experiences double
7 pathological insults –both intrinsic and extrinsic– during ALS progression, leading to severe
8 atrophy in a very short period of time (3–5 years) after the onset of the ALS symptoms [38].

14 *Signals for drugs used in ALS patients*

16
17 Among other signals that we detected, several drugs belong to the symptomatic treatment
18 offered to ALS patients in order to control and delay the disease process. We could therefore
19 exclude the following drugs from hypotheses on the biological plausibility of adverse drug
20 effects:
21

- 22 • riluzole and edaravone (both used as treatments of choice for ALS [39]);
- 23 • dextromethorphan and quinidine combination (authorized for pseudobulbar syndrome
24 in ALS patients in the US [40]);
- 25 • quinine (used to treat cramps [41])
- 26 • muscle-relaxant agents (tizanidine, baclofen, and botulinum toxin used to reduce
27 spasticity in ALS patients [42]);
- 28 • benzodiazepines (lorazepam, to treat both spasticity and anxiety symptoms [43]);
- 29 • immunomodulatory agents (interferon beta-1b, tested in ALS because it might interfere
30 with immune mechanisms involved in the pathogenesis of the disease [44,45]);
- 31 • cholecalciferol (offered to contrast neuroinflammation and also because the impact of
32 vitamin D deficiency is considered a favoring factor in various central or peripheral
33 neurological diseases such as ALS [46]);
- 34 • antidepressant agents (paroxetine, escitalopram, duloxetine, used in ALS to treat
35 depression, excessive salivation for their anticholinergic side effects, and emotional
36

1 outbursts [47,40]). Moreover, as for other neurodegenerative conditions, depression
2 may be a prodromal symptom of ALS. Although motor symptoms are traditionally
3 perceived as the first and main symptoms of ALS, the involvement of nonmotor
4 symptoms both at the onset and after the debut of motor symptoms is likely [47]. This
5 case represents an additional reason for reporting ALS after antidepressant use.
6
7
8
9

- 10 • NSAIDs (used to treat pain, which commonly affects limbs, trunk, and neck in all stages
11 of ALS and becomes more common as the disease progresses [40]).
12
13
14
15
16

17 Nevertheless, it has to be said we cannot totally exclude a role in ALS development for some
18 of the agents listed above. As an example, quinine and quinidine, as well as
19 hydroxychloroquine, might contribute to the worsening of ALS by antagonizing acetylcholine
20 on its nicotinic receptors [48]. At the same time, we cannot exclude that some other promising
21 drug is affected by reverse causality bias. In fact, the ALS presymptomatic stage could last also
22 for years [49], and early non-motor symptoms have been increasingly recognized in the disease
23 [50], increasing the possibility of confounders in this kind of retrospective studies. Thus, we
24 emphasize that the results generated in the present study should be interpreted with caution.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Role of gut microbiota

66 Finally, ALS development seems to be connected with gut dysbiosis and altered intestinal
67 permeability, although the precise biological mechanisms underlying such a relationship
68 remain to be clarified [8]. It is noteworthy that several classes of drugs with an ALS signal in
69 FAERS are known to alter intestinal microbiota: statins, by interacting with bile acids and
70 impacting upon expression of inflammatory markers that influence microbial community
71 structure; antineoplastic agents, for which a mechanistic framework of interaction with
72 microbiome was recently described (TIMER - Translocation, Immunomodulation,
73
74
75

1 Metabolism, Enzymatic degradation and Reduced diversity); NSAIDs, by altering the function
2 of the small intestine; antihypertensive drugs, for which animal data suggested interaction with
3
4 gut microbiota [51,52].
5

6 ***Limitations and Strengths***

7
8
9 The analysis of spontaneous reporting data allows for a cheap and timely detection of
10 unexpected drug-event disproportionalities. It collects a great number of reports from a large
11 heterogeneity of environments and accounts for a complexity that is usually excluded from
12 randomized clinical trials (e.g., comorbidity, polytherapy, misuse, extreme ages). Nonetheless,
13 it does not allow formal risk assessment and requires considering multiple biases and
14 limitations. Underreporting is an important problem, particularly for multifactorial and delayed
15 onset events such as ALS is thought to be, therefore spontaneous reporting systems cannot be
16 used to calculate incidence. Furthermore, reports are submitted on a spontaneous basis, both
17 by doctors and consumers, and are often unverified. To account for inter-reporter
18 heterogeneity in the choice of terms, partly due to the redundancy of the MedDRA, we
19 extended the case codification for the broader analysis. We also discussed the reverse causality
20 bias and prioritized disproportionality signals with ROR stability on multiple sensitivity
21 analyses.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **5. CONCLUSIONS**

45 With this pharmacovigilance analysis, we detected drugs disproportionately reported with ALS
46 and discussed their potential role. Our findings strengthened the plausibility of a precipitating
47 role of drugs primarily through immunomodulation (e.g., TNF- α , ustekinumab, omalizumab),
48 but also by impacting metabolism and the musculoskeletal integrity (e.g., statins and
49 bisphosphonates). Our findings provide a useful background for planning large cohort studies
50 to reinforce or weaken the plausibility of a causal role for specific drugs in the development of
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ALS. They also represent an input for translational research on mechanisms of ALS and on relevant possible therapeutic strategies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ACKNOWLEDGMENTS

The authors are supported by institutional research funds (Ricerca Fondamentale Orientata) from the University of Bologna. The authors thank Ippazio Cosimo Antonazzo from the University of Milano-Bicocca for his support in data analysis planning.

DECLARATIONS

Funding: No specific funding was received for this research.

Conflicts of interest: Authors do not have conflicts of interest

Ethics approval: Not applicable

Consent to participate: Not applicable

Consent for publication: Not applicable

Data availability: The data that support the findings of this study were downloaded from the FAERS quarterly data, available to the public at the following link:
<https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html>

Code availability: The R script developed for the analyses is available from the corresponding author upon reasonable request.

Authors contribution: EB, FN, FD, JM, and EP conceived the project, reviewed the manuscript. AG and FM wrote the original draft of the manuscript. AG and FM, performed the investigation, carried out the analyses, and interpreted data. FM performed the investigation, carried out the analyses, interpreted data, and administered the project. EB, LV, FN, JM, and EP contributed to methodological issues, supervised the project, and reviewed the manuscript. FD and EP administered the project. All the authors read and approved the final version.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Tables and Figures legends:

Table 1: Synopsis of disproportionality signals of ALS

REFERENCES

1. Oskarsson B, Gendron TF, Staff NP. Amyotrophic Lateral Sclerosis: An Update for 2018. *Mayo Clin Proc.* 2018;93:1617-1628. doi:10.1016/j.mayocp.2018.04.007
2. Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis. *Am J Manag Care.* 2018;24:S327-S335.
3. Jaiswal MK. Calcium, mitochondria and the pathogenesis of ALS: the good, the Bad and the ugly. *Front Cell Neurosci.* 2013;7:199. doi: 10.3389/fncel.2013.00199
4. Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. *Eur J Neurol.* 2020;27:1010-1016. doi:https://doi.org/10.1111/ene.14190
5. Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, et al. No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study. *Sci Rep.* 2020;10:13371. doi:10.1038/s41598-020-70373-8
6. Freedman DM, Kuncel RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. *Amyotroph Lateral Scler Front Degener.* 2018;19:538-546. doi:10.1080/21678421.2018.1511731
7. Arkema EV, Feltelius N, Olsson T, Askling J. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment. *Ann Rheum Dis.* 2014;73:2061-2062. doi:10.1136/annrheumdis-2014-205622
8. Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. *Eur J Neurol.* 2019;26:1355-1361. doi:https://doi.org/10.1111/ene.13986

- 1
2 9. Raschi E, Moretti U, Salvo F, Pariente A, Antonazzo IC, De Ponti F, et al. Evolving
3 Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety.
4 IntechOpen; 2018. doi:10.5772/intechopen.79986
5
- 6
7 10. Antonazzo IC, Raschi E, Forcesi E, Riise T, Bjernevik K, Baldin E, et al. Multiple
8 sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting
9 System. *Expert Opin Drug Saf.* 2018;17:869-874. doi:10.1080/14740338.2018.1506763
10
11
- 12
13 11. Poluzzi E, Raschi E, Piccinni C, Ponti FD. Data Mining Techniques in
14 Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting
15 System (AERS). IntechOpen; 2012. doi:10.5772/50095
16
17
- 18
19 12. Harpaz R, DuMouchel W, LePendu P, Bauer- Mehren A, Ryan P, Shah NH.
20 Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse
21 Event Reporting System. *Clin Pharmacol Ther.* 2013;93:539-546.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
13. Petitpain N, Devos D, Bagheri H, Rocher F, Gouraud A, Masmoudi K, et al. Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis? *Fundam Clin Pharmacol.* 2019;33:689-694. doi:https://doi.org/10.1111/fcp.12480
14. Bahia El Idrissi N, Bosch S, Ramaglia V, Aronica E, Baas F, Troost D. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. *J Neuroinflammation.* 2016;13:72.. doi:10.1186/s12974-016-0538-2
15. Woodruff TM, Lee JD, Noakes PG. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. *Proc Natl Acad Sci U S A.* 2014;111:E3-E4. doi:10.1073/pnas.1321248111
16. Parker SE, Hanton AM, Stefanou SN, Noakes PG, Woodruff TM, Lee JD. Revisiting the role of the innate immune complement system in ALS. *Neurobiol Dis.* 2019;127:223-232. doi:10.1016/j.nbd.2019.03.003

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
17. Alexion Pharmaceuticals. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS). [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT04248465); 2021. Accessed May 18, 2021.
<https://clinicaltrials.gov/ct2/show/NCT04248465>
 18. Apellis Pharmaceuticals, Inc. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS). [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT04579666); 2021. Accessed May 18, 2021. <https://clinicaltrials.gov/ct2/show/NCT04579666>
 19. Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, et al. NF- κ B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. *EMBO J*. 2018;37:e98697. doi:10.15252/embj.201798697
 20. Bougea A, Anagnostou E, Stamboulis E, Kararizou E. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. *Rev Neurol (Paris)*. 2014;170:228-229. doi:10.1016/j.neurol.2013.11.004
 21. Aj GA. Development of Amyotrophic Lateral Sclerosis during Ustekinumab use for Refractory Crohn's Disease. 2017;2:2.
 22. Varan O, Kucuk H, Tufan A. Myasthenia gravis due to hydroxychloroquine. *Reumatismo*. 2016;67:125. doi:10.4081/reumatismo.2015.849
 23. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. *Nat Rev Immunol*. 2018;18:5-18. doi:10.1038/nri.2017.97
 24. Marchi LF, Paoliello-Paschoalato AB, Oliveira RDR, Azzolini AECS, Kabeya LM, Donadi EA, et al. Activation status of peripheral blood neutrophils and the complement system in adult rheumatoid arthritis patients undergoing combined therapy with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

infliximab and methotrexate. *Rheumatol Int.* 2018;38:1043-1052. doi:10.1007/s00296-018-3997-1

25. Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, et al. The kinase inhibitor imatinib mesylate inhibits TNF- α production in vitro and prevents TNF-dependent acute hepatic inflammation. *Proc Natl Acad Sci U S A.* 2005;102:13622-13627. doi:10.1073/pnas.0501758102
26. Palomo V, Nozal V, Rojas- Prats E, Gil C, Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. *Br J Pharmacol.* 2021;178:1316-1335. doi:<https://doi.org/10.1111/bph.15221>
27. Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. *Amyotroph Lateral Scler Front Degener.* 2020;21:5-14. doi:10.1080/21678421.2019.1632346
28. Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. *Drug Saf.* 2018;41:403-413. doi:10.1007/s40264-017-0620-4
29. Law M, Rudnicka AR. Statin Safety: A Systematic Review. *Am J Cardiol.* 2006;97:S52-S60. doi:10.1016/j.amjcard.2005.12.010
30. Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, et al. Drug-Induced Peripheral Neuropathy: A Narrative Review. *Curr Clin Pharmacol.* 2020;15:38-48. doi:10.2174/1574884714666190121154813
31. Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? *Amyotroph Lateral Scler.* 2008;9:223-228. doi:10.1080/17482960802031092

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
32. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. *Int J Clin Pract.* 2008;62:88-96.
doi:<https://doi.org/10.1111/j.1742-1241.2007.01592.x>
 33. Moglia C, Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. *Amyotroph Lateral Scler Front Degener.* 2017;18:590-597.
doi:10.1080/21678421.2017.1336560
 34. Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, et al. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. *Eur J Neurol.* 2018;25:861-868. doi:10.1111/ene.13620
 35. Mallette LE, Patten B, Cook JD, Engel WK. Calcium metabolism in amyotrophic lateral sclerosis. *Dis Nerv Syst.* 1977;38:457-461.
 36. Peters TL, Weibull CE, Fang F, Sandler DP, Lambert PC, Ye W, et al. Association of Fractures with the Incidence of Amyotrophic Lateral Sclerosis. *Amyotroph Lateral Scler Front Degener.* 2017;18:419-425. doi:10.1080/21678421.2017.1300287
 37. Chen X, Wang K, Wang Z, Gan C, He P, Liang Y, et al. Effects of lead and cadmium co-exposure on bone mineral density in a Chinese population. *Bone.* 2014;63:76-80.
doi:10.1016/j.bone.2014.02.017
 38. Zhou J, Yi J, Bonewald L. Muscle-Bone Crosstalk in Amyotrophic Lateral Sclerosis. *Curr Osteoporos Rep.* 2015;13:274-279. doi:10.1007/s11914-015-0281-0
 39. Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. *Med Res Rev.* 2019;39:733-748. doi:<https://doi.org/10.1002/med.21528>
 40. Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. *Nat Rev Neurol.* 2016;12:526-538. doi:10.1038/nrneurol.2016.111

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
41. Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. *Cochrane Database Syst Rev.* 2012;.
doi:10.1002/14651858.CD004157.pub2
 42. Park J, Park HJ. Botulinum Toxin for the Treatment of Neuropathic Pain. *Toxins.* 2017;9:260. doi:10.3390/toxins9090260
 43. Beeldman E, Raaphorst J, Twennaar MK, Visser M de, Schmand BA, Haan RJ de. The cognitive profile of ALS: a systematic review and meta-analysis update. *J Neurol Neurosurg Psychiatry.* 2016;87:611-619. doi:10.1136/jnnp-2015-310734
 44. Dumitrescu L, Constantinescu CS, Tanasescu R. Recent developments in interferon-based therapies for multiple sclerosis. *Expert Opin Biol Ther.* 2018;18:665-680. doi:10.1080/14712598.2018.1462793
 45. Beghi E, Chiò A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. *Neurology.* 2000;54:469-469. doi:10.1212/WNL.54.2.469
 46. Mpandzou G, Aït Ben Haddou E, Regragui W, Benomar A, Yahyaoui M. Vitamin D deficiency and its role in neurological conditions: A review. *Rev Neurol (Paris).* 2016;172:109-122. doi:10.1016/j.neurol.2015.11.005
 47. Roos E, Mariosa D, Ingre C, Lundholm C, Wirdefeldt K, Roos PM, et al. Depression in amyotrophic lateral sclerosis. *Neurology.* 2016;86:2271-2277. doi:10.1212/WNL.0000000000002671
 48. Gisselmann G, Alisch D, Welbers-Joop B, Hatt H. Effects of Quinine, Quinidine and Chloroquine on Human Muscle Nicotinic Acetylcholine Receptors. *Front Pharmacol.* 2018;9:1339. doi:10.3389/fphar.2018.01339

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
49. Benatar M, Turner MR, Wu J. Defining pre-symptomatic amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Front Degener.* 2019;20:303–9. doi: 10.1080/21678421.2019.1587634
 50. Zucchi E, Ticozzi N, Mandrioli J. Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder. *Front Neurosci.* 2019;13:175. doi: 10.3389/fnins.2019.00175.
 51. Le Bastard Q, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. *Aliment Pharmacol Ther.* 2018;47:332-345. doi:10.1111/apt.14451
 52. Tuteja Sony, Ferguson Jane F. Gut Microbiome and Response to Cardiovascular Drugs. *Circ Genomic Precis Med.* 2019;12:e002314. doi:10.1161/CIRCGEN.119.002314

Table 1: Synopsis of disproportionality signals of ALS

Class	Subclass	Drugs ATC code	Disproportionality signals*
ALIMENTARY TRACT AND METABOLISM DRUGS	<i>VITAMINS</i>	Colecalciferol A11CC	1 drug with Low ROR stability
BLOOD AND BLOOD FORMING ORGANS DRUGS	<i>ANTI-ANEMIC PREPARATIONS</i>	Mecobalamin B03BA	1 drug with Intermediate ROR stability
CARDIOVASCULAR SYSTEM DRUGS	<i>CARDIAC THERAPY</i>	Quinidine C01BA Ubidecarenone C01EB	1 drug with Top ROR stability 1 drug with Intermediate ROR stability
	<i>DIURETICS</i>	Bendroflumethiazide C03AA	1 drug with Low ROR stability
	<i>BETA BLOCKING AGENTS</i>	Sotalol C07AA Atenolol C07AB Bisoprolol C07AB	2 drugs with Top ROR stability 1 drug with Low ROR stability
	<i>CALCIUM CHANNEL BLOCKERS</i>	Verapamil C08DA	1 drug with Intermediate ROR stability
	<i>AGENTS ACTING ON THE RENIN – ANGIOTENSIN SYSTEM</i>	Enalapril C09AA Perindopril C09AA Candesartan C09CA Olmesartan C09CA	1 drug with Top ROR stability 1 drug with High ROR stability 1 drug with Intermediate ROR stability 1 drug with Low ROR stability
	<i>LIPID MODIFYING AGENTS</i>	Atorvastatin C10AA Cerivastatin C10AA Fluvastatin C10AA Lovastatin C10AA Pitavastatin C10AA Pravastatin C10AA Rosuvastatin C10AA Simvastatin C10AA Fenofibrate C10AB Colestyramine C10AC Ezetimibe C10AX	9 drugs with Top ROR stability 1 drug with Intermediate ROR stability 1 drug with Low ROR stability
DERMATOLOGICALS DRUGS	<i>OTHER DERMATOLOGICALS PREPARATIONS</i>	Glycopyrronium D11AA	1 drug with Intermediate ROR stability
GENITO-URINARY SYSTEM AND SEX HORMONES DRUGS	<i>UROLOGICALS</i>	Dutasteride G04CB	1 drug with Intermediate ROR stability

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	<i>ANTINEOPLASTIC AGENTS</i>	Bendamustine L01AA Methotrexate L01BA Rituximab L01XC Imatinib L01XE	3 drugs with Top ROR stability 1 drug with low ROR stability
	<i>ENDOCRINE THERAPY</i>	Letrozole L02BG	1 drug with Low ROR stability
	<i>IMMUNOSTIMULANTS</i>	interferon beta-1b L03AB	1 drug with Intermediate ROR stability
	<i>IMMUNOSUPPRESSANTS</i>	Abatacept L04AA Leflunomide L04AA Natalizumab L04AA Tofacitinib L04AA Adalimumab L04AB Etanercept L04AB Infliximab L04AB Tocilizumab L04AC Ustekinumab L04AC	7 drugs with Top ROR stability 1 drug with High ROR stability 1 drug with Intermediate ROR stability
MUSCULO-SKELETAL SYSTEM DRUGS	<i>ANTINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</i>	diclofenac * M01AB celecoxib * M01AH chondroitin M01AX	1 drug with Top ROR stability 1 drug with Intermediate ROR stability 1 drug with Low ROR stability
	<i>MUSCLE RELAXANTS</i>	botulinum toxin M03AX baclofen M03BX tizanidine M03BX	2 drugs with Top ROR stability 1 drug with Intermediate ROR stability
	<i>DRUGS FOR TREATMENT OF BONE DISEASES</i>	alendronic acid M05BA risedronic acid M05BA zoledronic acid M05BA	1 drug with Top ROR stability 1 drug with Intermediate ROR stability 1 drug with Low ROR stability
NERVOUS SYSTEM DRUGS	<i>ANTIPILEPTICS</i>	Phenytoin N03AB	1 drug with Intermediate ROR stability
	<i>PYSCHOLEPTICS</i>	Lorazepam N05BA Melatonin N05CH	2 drugs with Intermediate ROR stability
	<i>PSYCHOANALEPTICS</i>	Escitalopram N06AB Paroxetine N06AB Duloxetine N06AX	1 drug with Top ROR stability 1 drug with High ROR stability 1 drug with Intermediate ROR stability
	<i>OTHER NERVOUS SYSTEM DRUGS</i>	Edaravone N07XX Riluzole N07XX	2 drugs with High ROR stability
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	<i>ANTIPROTOZOALS</i>	Hydroxychloroquine P01BA Quinine P01BC	1 drug with Top ROR stability 1 drug with Intermediate ROR stability
RESPIRATORY SYSTEM DRUGS	<i>DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</i>	Omalizumab R03DX	1 drug with Top ROR stability

	<i>COUGH AND COLD PREPARATIONS</i>	Dextromethorphan R05DA	1 drug with Top ROR stability
--	--	------------------------	-------------------------------

*ROR stability: Top ROR stability - signal maintained in 4 out of 4 analyses; High ROR stability - signal maintained in 3 out of 4 analyses; Intermediate ROR stability: signal maintained in 2 out of 4 analyses; Low ROR stability - signal emerged only in 1 out of 4 analysis.

A disproportionality signal was defined when at least 5 cases were submitted, and the lower limit of the ROR 95%CI was higher than 1.